Trials / Completed
CompletedNCT06193148
A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants
A Study to Evaluate the Effect of Oral Administration of Jaktinib Hydrochloride Tablets on QT/Corrected QT (QTc) Interval in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the effect of Jaktinib Hydrochloride Tablets on QT/QTc interval in healthy subjects after a single oral administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib | Participants will receive Jaktinib orally for single dose |
| DRUG | Placebo | Participants will receive Placebo orally for single dose |
Timeline
- Start date
- 2024-03-19
- Primary completion
- 2024-06-18
- Completion
- 2024-06-18
- First posted
- 2024-01-05
- Last updated
- 2024-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06193148. Inclusion in this directory is not an endorsement.